Drug Trial Radar · NCT06790303
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Mar 4, 2021
Primary completion
Sep 23, 2021
Study completion Sep 23, 2021
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.
Conditions
- Neoplasms
Interventions
FeladilimabDrug
Feladilimab will be administered.
IpilimumabDrug
Ipilimumab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 29 weeks
- Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
- Part 1: Number of Participants With Worst-case Change Post-baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to 29 weeks
- Part 1: Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry ParametersTime frame: Baseline (Day 1) and up to 29 weeks
- Part 1: Number of Participants With Worst Case Change Post-baseline in Urinalysis ParametersTime frame: Baseline (Day 1) and up to 29 weeks
- Part 1: Change From Baseline in Potential of Hydrogen (pH) of UrineTime frame: Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)
- Part 1: Change From Baseline in Specific Gravity of UrineTime frame: Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)
- Part 1: Number of Participants With AE Leading to Dose ModificationsTime frame: Up to 29 weeks
- Part 2: Overall SurvivalTime frame: Up to 29 weeks
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Bordeaux, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.